Brought to you by 
GSK, Novartis must divest some assets; Perrigo buys OTC brands; Pfizer buys vaccines
03 Feb 2023
Executive Summary
The European Commission, which ensures that EU law is properly applied, approved GlaxoSmithKline PLC's three transactions in oncology, vaccines, and consumer health with Novartis AG (announced in April 2014), but the approval is subject to certain divestments the companies must make following closing of the deals. Buyers of the assets have not yet been disclosed.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
- Vaccines
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK, Novartis must divest some assets; Perrigo buys OTC brands; Pfizer buys vaccines
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice